In bladder cancer, ZBTB38 promotes migration and invasive growth [39], while in prostate cancer, depletion of ZBTB38 results in higher expression of ROS and elevated cell death after doxorubicin treatment [40]. Here, ZBTB38 is linked to prostate cancer.